Table 1.
Characteristics of Robert Wood Johnson Screening Study Participants
| All Participants (n = 3904)a | Negative on Both SARS-CoV-2 Virus and Antibody Test (n = 3523; 90.2%) | Positive on SARS-CoV-2 Virus or Antibody Test (n = 381; 9.8%) | ||
|---|---|---|---|---|
| Characteristics | N (Column %) | N (Row %) | N (Row %) | P Valueb |
| Demographics | ||||
| Gender | ||||
| Female | 2874 (74.0) | 2593 (90.2) | 281 (9.8) | .93 |
| Male | 1030 (26.0) | 930 (90.3) | 100 (9.7) | |
| Age (Years) | <.001 | |||
| 20–39 | 1703 (44.1) | 1502 (88.2) | 201 (11.8) | |
| 40–59 | 1690 (43.7) | 1548 (91.6) | 142 (8.4) | |
| ≥60 | 472 (12.2) | 439 (93.0) | 33 (7.0) | |
| Race Ethnicity | <.001 | |||
| Non-Hispanic white | 1612 (41.3) | 1492 (92.6) | 120 (7.4) | |
| Non-Hispanic black | 540 (13.8) | 460 (85.2) | 80 (14.8) | |
| Non-Hispanic Asian | 878 (22.5) | 819 (93.3) | 59 (6.7) | |
| Hispanic | 565 (14.5) | 478 (84.6) | 87 (15.4) | |
| Other/missing | 309 (7.9) | 1492 (92.6) | 120 (7.4) | |
| Clinical Variables | ||||
| BMI | ||||
| <18.5 | 94 (2.5) | 85 (90.4) | 9 (9.6) | .19 |
| 18.5 ≤ BMI < 25 | 1438 (38.2) | 1309 (91.0) | 129 (9.0) | |
| 25 ≤ BMI < 30 | 1271 (33.7) | 1154 (90.8) | 117 (9.2) | |
| 30 ≤ BMI < 40 | 827 (21.9) | 729 (88.1) | 98 (11.9) | |
| ≥40 | 139 (3.7) | 128 (92.1) | 11 (7.9) | |
| Tobacco Use | .25 | |||
| Never | 3175 (82.0) | 2855 (89.9) | 320 (10.1) | |
| Former | 459 (11.9) | 419 (91.3) | 40 (8.7) | |
| Current | 238 (6.1) | 221 (92.9) | 17 (7.1) | |
| Comorbidities | ||||
| No comorbidities | 1810 (48.2) | 1646 (90.9) | 164 (9.1) | .33 |
| Diabetes | 257 (6.7) | 234 (91.1) | 23 (8.9) | .73 |
| High blood pressure | 729 (18.9) | 666 (91.4) | 63 (8.6) | .28 |
| Asthma | 548 (14.3) | 495 (90.3) | 53 (9.7) | .99 |
| Obesity | 966 (25.6) | 857 (88.7) | 109 (11.3) | .055 |
| Otherc | 173 (4.5) | 158 (91.3) | 15 (8.7) | .74 |
| Recent COVID-19 symptoms (any) | 738 (19.2) | 640 (86.7) | 98 (13.3) | <.001 |
| Prior or recent COVID-19 symptoms (any) | 1404 (36.6) | 1175 (83.7) | 229 (16.3) | <.001 |
| Health Exposures | ||||
| Direct Patient Care | .02 | |||
| No | 1171 (31.2) | 1076 (91.9) | 95 (8.1) | |
| Yes, close contact (≤40% of total worktime) | 1358 (36.2) | 1227 (90.4) | 131 (9.6) | |
| Yes, close contact (>40% of total worktime) | 1226 (32.6) | 1085 (88.5) | 141 (11.5) | |
| Household member with COVID-19 diagnosis or symptoms | 208 (5.3) | 161 (77.4) | 47 (22.6) | <.001 |
| Coworker with COVID-19 diagnosis or symptoms | 1108 (28.5) | 988 (89.2) | 120 (10.8) | .15 |
| Other contact with COVID-19 diagnosis or symptoms | 296 (7.6) | 258 (87.2) | 38 (12.8) | .08 |
| Hospital Role | <.001 | |||
| Dentist/Dental | 22 (0.6) | 22 (100.0) | 0 (0.0) | |
| Dining/Food | 89 (2.3) | 74 (83.1) | 15 (16.9) | |
| Interpersonal/Support | 351 (9.0) | 303 (86.3) | 48 (13.7) | |
| Maintenance/Housekeeping | 150 (3.8) | 124 (82.7) | 26 (17.3) | |
| Nonphysician Emergency Workers | 13 (0.3) | 12 (92.3) | 1 (7.7) | |
| NP/PA | 159 (4.1) | 137 (86.2) | 22 (13.8) | |
| Nurse/Trainee | 1239 (31.7) | 1122 (90.6) | 117 (9.4) | |
| OR/Surgical Staff | 54 (1.4) | 52 (96.3) | 2 (3.7) | |
| Other Nonpatient Care | 433 (11.1) | 411 (94.9) | 22 (5.1) | |
| Other Patient Care | 136 (3.5) | 117 (86.0) | 19 (14.0) | |
| Pharmacist | 115 (2.9) | 113 (98.3) | 2 (1.7) | |
| Phlebotomist | 46 (1.2) | 35 (76.1) | 11 (23.9) | |
| Physician/Trainee | 502 (12.9) | 466 (92.8) | 36 (7.2) | |
| PT/OT/ST | 98 (2.5) | 91 (92.9) | 7 (7.1) | |
| Respiratory | 56 (1.4) | 53 (94.6) | 3 (5.4) | |
| Technicians/Technologists | 399 (10.2) | 353 (88.5) | 46 (11.5) | |
| Unclassified | 42 (1.1) | 38 (90.5) | 4 (9.5) |
Abbreviations: BMI, body mass index; COVID-19, coronavirus disease 2019; NP, nurse practitioner; OR, operating room; OT, occupational therapist; PA, physician’s assistant; PT, physical therapist; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; ST, speech therapist.
an for individual variables vary with some missing data from up to 4% of respondents.
bBold font indicates P < .05.
cOther comorbidities include the following: cancer, cardiovascular or cerebrovascular disease, chronic autoimmune disease, chronic kidney disease, chronic obstructive pulmonary disease, or other chronic lung disease.